126 related articles for article (PubMed ID: 10595485)
1. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy.
Welsh JS; Yanez MH; Chin BB; Howard SP
Clin Nucl Med; 1999 Dec; 24(12):983. PubMed ID: 10595485
[No Abstract] [Full Text] [Related]
2. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
3. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
ProaƱo JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
4. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
[TBL] [Abstract][Full Text] [Related]
5. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
6. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
9. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
Petronis JD; Regan F; Lin K
Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
[TBL] [Abstract][Full Text] [Related]
10. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
11. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
12. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
Shore ND
Urology; 2010 Nov; 76(5):1167-8; author reply 1168. PubMed ID: 21056261
[No Abstract] [Full Text] [Related]
15. Indium-111-capromab pendetide scans: an important test relevant to clinical decision making.
Sartor O; McLeod D
Urology; 2001 Mar; 57(3):399-401. PubMed ID: 11248605
[No Abstract] [Full Text] [Related]
16. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients.
Quintana JC; Blend MJ
Clin Nucl Med; 2000 Jan; 25(1):33-40. PubMed ID: 10634528
[TBL] [Abstract][Full Text] [Related]
17. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney.
Valliappan S; Joyce JM; Myers DT
Clin Nucl Med; 1999 Dec; 24(12):984-5. PubMed ID: 10595486
[No Abstract] [Full Text] [Related]
18. Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis.
Khan A; Caride VJ
Urology; 2000 Jul; 56(1):154. PubMed ID: 10869655
[TBL] [Abstract][Full Text] [Related]
19. Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging.
Manyak MJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):127-30. PubMed ID: 10803317
[No Abstract] [Full Text] [Related]
20. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
Sodee DB; Conant R; Chalfant M; Miron S; Klein E; Bahnson R; Spirnak JP; Carlin B; Bellon EM; Rogers B
Clin Nucl Med; 1996 Oct; 21(10):759-67. PubMed ID: 8896922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]